^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | trastuzumab imbotolimod (BDC-1001) (HER2 inhibitor, TLR8 agonist, TLR7 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1/2 Study of BDC 1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors. Studio di fase I/II su BDC-1001 in monoterapia e in combinazione con nivolumab in pazienti affetti da tumori solidi avanzati con espressione di HER2.
Excerpt:
...1.For P.1 and P.2:a.Pt has an advanced solid tumor for which approved therapies have been exhausted or for which the Investigator considers the patient ineligible or intolerant of other forms of treatmentbTumor has documented HER2 expression. ...
Trial ID:
Source:
Title:
657MO - Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
Published date:
10/16/2023
Excerpt:
Our novel ISAC BDC-1001 (mono/combo) led to tolerable, encouraging efficacy, translational biomarker data consistent with novel MOA in pts with pretreated HER2+ tumors, particularly at the 20mg/kg q2w RP2D.
Trial ID:
